Vanguard Group
SRPT icon

Vanguard Group’s Sarepta Therapeutics SRPT Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$157M Buy
9,160,179
+127,566
+1% +$2.18M ﹤0.01% 1629
2025
Q1
$576M Sell
9,032,613
-52,843
-0.6% -$3.37M 0.01% 913
2024
Q4
$1.1B Buy
9,085,456
+117,904
+1% +$14.3M 0.02% 626
2024
Q3
$1.12B Sell
8,967,552
-68,072
-0.8% -$8.5M 0.02% 627
2024
Q2
$1.43B Buy
9,035,624
+239,870
+3% +$37.9M 0.03% 534
2024
Q1
$1.14B Sell
8,795,754
-20,370
-0.2% -$2.64M 0.02% 610
2023
Q4
$850M Buy
8,816,124
+243,180
+3% +$23.4M 0.02% 680
2023
Q3
$1.04B Buy
8,572,944
+41,465
+0.5% +$5.03M 0.03% 591
2023
Q2
$977M Buy
8,531,479
+418,515
+5% +$47.9M 0.02% 622
2023
Q1
$1.12B Buy
8,112,964
+79,700
+1% +$11M 0.03% 563
2022
Q4
$1.04B Sell
8,033,264
-52,253
-0.6% -$6.77M 0.03% 565
2022
Q3
$894M Sell
8,085,517
-334,530
-4% -$37M 0.03% 604
2022
Q2
$631M Buy
8,420,047
+104,865
+1% +$7.86M 0.02% 737
2022
Q1
$650M Buy
8,315,182
+4,074
+0% +$318K 0.02% 811
2021
Q4
$748M Buy
8,311,108
+830,457
+11% +$74.8M 0.02% 776
2021
Q3
$692M Buy
7,480,651
+24,249
+0.3% +$2.24M 0.02% 796
2021
Q2
$580M Buy
7,456,402
+90,302
+1% +$7.02M 0.01% 900
2021
Q1
$549M Buy
7,366,100
+148,842
+2% +$11.1M 0.01% 900
2020
Q4
$1.23B Buy
7,217,258
+126,076
+2% +$21.5M 0.04% 517
2020
Q3
$996M Sell
7,091,182
-26,515
-0.4% -$3.72M 0.03% 515
2020
Q2
$1.14B Buy
7,117,697
+572,908
+9% +$91.9M 0.04% 460
2020
Q1
$640M Buy
6,544,789
+160,001
+3% +$15.7M 0.03% 577
2019
Q4
$824M Buy
6,384,788
+19,558
+0.3% +$2.52M 0.03% 610
2019
Q3
$479M Buy
6,365,230
+132,806
+2% +$10M 0.02% 807
2019
Q2
$947M Buy
6,232,424
+232,752
+4% +$35.4M 0.04% 531
2019
Q1
$715M Buy
5,999,672
+134,349
+2% +$16M 0.03% 617
2018
Q4
$640M Buy
5,865,323
+480,424
+9% +$52.4M 0.03% 600
2018
Q3
$870M Buy
5,384,899
+170,999
+3% +$27.6M 0.03% 564
2018
Q2
$689M Buy
5,213,900
+60,323
+1% +$7.97M 0.03% 625
2018
Q1
$382M Buy
5,153,577
+72,519
+1% +$5.37M 0.02% 888
2017
Q4
$283M Buy
5,081,058
+145,275
+3% +$8.08M 0.01% 1064
2017
Q3
$224M Buy
4,935,783
+676,754
+16% +$30.7M 0.01% 1191
2017
Q2
$144M Buy
4,259,029
+162,543
+4% +$5.48M 0.01% 1462
2017
Q1
$121M Buy
4,096,486
+176,966
+5% +$5.24M 0.01% 1548
2016
Q4
$108M Buy
3,919,520
+239,175
+6% +$6.56M 0.01% 1573
2016
Q3
$226M Buy
3,680,345
+574,529
+18% +$35.3M 0.01% 1034
2016
Q2
$59.2M Buy
3,105,816
+161,790
+5% +$3.09M ﹤0.01% 1822
2016
Q1
$57.5M Buy
2,944,026
+103,897
+4% +$2.03M ﹤0.01% 1803
2015
Q4
$110M Buy
2,840,129
+268,538
+10% +$10.4M 0.01% 1401
2015
Q3
$82.6M Buy
2,571,591
+69,418
+3% +$2.23M 0.01% 1571
2015
Q2
$76.1M Buy
2,502,173
+78,763
+3% +$2.4M 0.01% 1710
2015
Q1
$32.2M Buy
2,423,410
+132,696
+6% +$1.76M ﹤0.01% 2129
2014
Q4
$33.1M Buy
2,290,714
+82,961
+4% +$1.2M ﹤0.01% 2025
2014
Q3
$46.6M Sell
2,207,753
-22,198
-1% -$468K ﹤0.01% 1834
2014
Q2
$66.4M Buy
2,229,951
+126,020
+6% +$3.75M 0.01% 1678
2014
Q1
$50.6M Buy
2,103,931
+42,593
+2% +$1.02M ﹤0.01% 1800
2013
Q4
$42M Buy
2,061,338
+326,375
+19% +$6.65M ﹤0.01% 1872
2013
Q3
$81.9M Buy
1,734,963
+127,967
+8% +$6.04M 0.01% 1380
2013
Q2
$61.1M Buy
+1,606,996
New +$61.1M 0.01% 1493